Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Cambridge Cognition Holdings ( (GB:COG) ).
Cambridge Cognition Holdings announced that its investment, Monument Therapeutics, has achieved positive Phase I clinical trial results for MT1988, a novel treatment for cognitive impairment associated with schizophrenia. This milestone demonstrates favorable safety and tolerability profiles, supporting the advancement to Phase II development. The success of MT1988, which addresses a critical unmet need in schizophrenia treatment, is expected to enhance the company’s value through potential future royalties and reinforces its position in the brain health industry.
More about Cambridge Cognition Holdings
Cambridge Cognition is a brain health software group specializing in digital health products aimed at advancing brain health research and treatment. The company focuses on four market sectors: clinical studies for new pharmaceuticals, academic research, healthcare for cognitive assessments, and consumer health & wellness. They create shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.
Average Trading Volume: 16,339
Technical Sentiment Signal: Strong Sell
Current Market Cap: £15.49M
For an in-depth examination of COG stock, go to TipRanks’ Overview page.